Thus, the combination of adavosertib and PD-L1 blockade induces tumor regression, activation of type I and II interferon pathways, and infiltration of cytotoxic T cells in SCLC mouse models, representing a promising immunotherapeutic approach in SCLC [97]. Here, SGCG is linked to small cell lung carcinoma.